Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2003

View Archived Issues

Three series of 5-HT2C agonists for schizophrenia and obesity claimed by Wyeth

New agents for Flaviviridae infections covered by ViroPharma patent

Nippon Shinyaku presents novel antipruritic agents

Sumitomo researchers design novel ACAT inhibitors for arteriosclerosis therapy

New MMP-13 inhibitors identified at Takeda

Yamanouchi scientists prepare and test new glycogen phosphorylase inhibitors

Antitumor effects of the HLA-DR-specific MAb 1D09C3 shown in vitro and in vivo

CGP-76030 inhibits proliferation of imatinib-resistant, Bcr/Abl-transformed murine bone marrow cells

Enhanced apoptosis with LAQ-824 and Apo2L/TRAIL cotreatment

CC-5079 induces NF-B-independent apoptosis of hematopoietic cancer cells

Potent in vitro effects of OSW-1 against human leukemia cells

U.S. launch of Risperdal Consta

Allos completes RSR-13 NDA filing

Treatment commences in pivotal European phase II trial of clofarabine for ALL

Collegium and Endo to develop abuse-resistant opioids

Discovery Partners and Allergan enter lead discovery collaboration

PDE4 inhibitor AWD-12-281 progresses through the clinic

ETC-1001 safe and well tolerated in phase I study

GBTherapeutics cleared to begin Canadian phase Ia trial of GT-1061

Emory University, GSK and NIMH team up to tackle depression and mood disorders

Cipralex approved in select European countries for social anxiety disorder

Immunomedics updates progress of key antibody product candidates

New site added to international phase II study of Litx

Merck & Co. and Actelion join forces to develop renin inhibitors

MLN-2704 granted fast track designation

First NO compound from Merck/NitroMed partnership enters clinical testing

Certican completes European mutual recognition procedure

Phytopharm cleared to commence phase I testing of PYM-50018 for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...